DRUGABILIS is an established preclinical CRO specialized in assessing the pharmaceutical drugability of early R&D compounds, including cytotoxic drugs. Our expertise includes Early Formulation, from animal formulation (efficacy, PK, Tox) to early clinical formulation feasibility assessment (oral low soluble, injectable, topical) and API Solid Form Characterization and Optimization (salts, polymorphs). With about 300 clients supported over 21 years, our experience often makes the difference !